Sichuan Kelun Pharmaceutical Co Ltd (002422):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Sichuan Kelun Pharmaceutical Co Ltd (002422) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8094
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:35
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:中国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Sichuan Kelun Pharmaceutical Co., Ltd. (Kelun) is engaged in manufacturing and distribution of IV Solutions. The company’s products portfolio includes glucose injection, sodium chloride injection, glucose and sodium chloride injection, ringer’s injection, lactated ringer’s injection, compound amino acid injection, alanyl glutamine injection, compound amino acids, fat emulsion injection, vitamin c and glucose injection, vitamin c and sodium chloride injection, among others. It also offers products to serve parenteral nutrition, digestive system, cardiovascular, antipsychotic, respiratory system, anti-pathogenic microorganisms, and APIs and intermediates. The company is also involved in research and development of pharmaceutical products. Kelun is headquartered in Chengdu, Sichuan, China.

Sichuan Kelun Pharmaceutical Co Ltd (002422) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Sichuan Kelun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Sichuan Kelun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Sichuan Kelun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Sichuan Kelun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Sichuan Kelun Pharmaceutical Co Ltd, Medical Devices Deals, 2012 to YTD 2018 9
Sichuan Kelun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Sichuan Kelun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deal Details 12
Debt Offering 12
Sichuan Kelun Pharma to Raise USD63.3 Million in Private Placement of Bonds Due 2018 12
Sichuan Kelun Pharma Raises USD111.2 Million in Public Offering of 5.65% 2018 Second Tranche Notes 13
Sichuan Kelun Pharma Raises USD79 Million in Public Offering of 6.2% 2018 First Tranche Notes Due 2021 14
Sichuan Kelun Pharma Raises USD210 Million in First Tranche of Public Offering of 5.38% Notes Due 2020 15
Sichuan Kelun Pharma Raises USD206.9 Million in Second Tranche of Public Offering 16
Sichuan Kelun Pharma Raises USD88.6 Million in Public Offering of 5.38% Bonds Due 2020 17
Sichuan Kelun Pharma Raises USD58 Million in Public Offering of 4.89% Bonds Due 2022 18
Sichuan Kelun Pharma Raises USD72.7 Million in Public Offering of Bonds 19
Sichuan Kelun Pharma Completes Public Offering Of Bonds Due 2018 For US$175 Million 20
Sichuan Kelun Pharma Completes Public Offering Of Bonds Due 2017 For US$238 Million 21
Sichuan Kelun Pharma Announces Debt Offering Of Notes Due 2017 For US$412 Million 22
Acquisition 23
Sichuan Kelun Pharma to Acquire Xinjiang-Based Biomedicine company for USD3 Million 23
Sichuan Kelun Pharma Plans to Acquire 35% stake in Changshu-Based Biotechnology Company 24
Sichuan Kelun Pharma Plans to Acquire Remaining 20% stake in Guangxi-Based Pharmaceutical Unit for USD5.3 Million 25
Sichuan Kelun Pharma Acquires KLUS Pharma for USD13 Million 26
Sichuan Kelun Pharma to Acquire 80% Stake in Biotechnology Company 27
Sichuan Kelun Pharma Plans to Acquire Remaining 15% Stake in Zhejiang-based pharmaceutical unit 28
Sichuan Kelun Pharma Acquires Guizhou Kelun Pharma, Pharmaceutical Preparations Manufacturer 29
Sichuan Kelun Pharma Acquires 56% Stake In Chengdu Pharma Company For US$32.8 Million 30
Sichuan Kelun Pharmaceutical Co Ltd – Key Competitors 31
Sichuan Kelun Pharmaceutical Co Ltd – Key Employees 32
Sichuan Kelun Pharmaceutical Co Ltd – Locations And Subsidiaries 33
Head Office 33
Other Locations & Subsidiaries 33
Affiliate 34
Appendix 35
Methodology 35
About GlobalData 35
Contact Us 35
Disclaimer 35

List of Tables
Sichuan Kelun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Sichuan Kelun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Sichuan Kelun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Sichuan Kelun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Sichuan Kelun Pharmaceutical Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Sichuan Kelun Pharmaceutical Co Ltd, Medical Devices Deals, 2012 to YTD 2018 9
Sichuan Kelun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Sichuan Kelun Pharma to Raise USD63.3 Million in Private Placement of Bonds Due 2018 12
Sichuan Kelun Pharma Raises USD111.2 Million in Public Offering of 5.65% 2018 Second Tranche Notes 13
Sichuan Kelun Pharma Raises USD79 Million in Public Offering of 6.2% 2018 First Tranche Notes Due 2021 14
Sichuan Kelun Pharma Raises USD210 Million in First Tranche of Public Offering of 5.38% Notes Due 2020 15
Sichuan Kelun Pharma Raises USD206.9 Million in Second Tranche of Public Offering 16
Sichuan Kelun Pharma Raises USD88.6 Million in Public Offering of 5.38% Bonds Due 2020 17
Sichuan Kelun Pharma Raises USD58 Million in Public Offering of 4.89% Bonds Due 2022 18
Sichuan Kelun Pharma Raises USD72.7 Million in Public Offering of Bonds 19
Sichuan Kelun Pharma Completes Public Offering Of Bonds Due 2018 For US$175 Million 20
Sichuan Kelun Pharma Completes Public Offering Of Bonds Due 2017 For US$238 Million 21
Sichuan Kelun Pharma Announces Debt Offering Of Notes Due 2017 For US$412 Million 22
Sichuan Kelun Pharma to Acquire Xinjiang-Based Biomedicine company for USD3 Million 23
Sichuan Kelun Pharma Plans to Acquire 35% stake in Changshu-Based Biotechnology Company 24
Sichuan Kelun Pharma Plans to Acquire Remaining 20% stake in Guangxi-Based Pharmaceutical Unit for USD5.3 Million 25
Sichuan Kelun Pharma Acquires KLUS Pharma for USD13 Million 26
Sichuan Kelun Pharma to Acquire 80% Stake in Biotechnology Company 27
Sichuan Kelun Pharma Plans to Acquire Remaining 15% Stake in Zhejiang-based pharmaceutical unit 28
Sichuan Kelun Pharma Acquires Guizhou Kelun Pharma, Pharmaceutical Preparations Manufacturer 29
Sichuan Kelun Pharma Acquires 56% Stake In Chengdu Pharma Company For US$32.8 Million 30
Sichuan Kelun Pharmaceutical Co Ltd, Key Competitors 31
Sichuan Kelun Pharmaceutical Co Ltd, Key Employees 32
Sichuan Kelun Pharmaceutical Co Ltd, Subsidiaries 33
Sichuan Kelun Pharmaceutical Co Ltd, Affiliate 34

List of Figures
Sichuan Kelun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Sichuan Kelun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Sichuan Kelun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Sichuan Kelun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Sichuan Kelun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Sichuan Kelun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Sichuan Kelun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Sichuan Kelun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Sichuan Kelun Pharmaceutical Co Ltd, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Sichuan Kelun Pharmaceutical Co Ltd (002422):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Toll Brothers Inc:戦略・SWOT・企業財務分析
    Toll Brothers Inc - Strategy, SWOT and Corporate Finance Report Summary Toll Brothers Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Indeck Energy Services Inc:企業の戦略的SWOT分析
    Indeck Energy Services Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • RRB Energy Ltd:企業の戦略的SWOT分析
    RRB Energy Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Titan Pharmaceuticals Inc (TTNP):医療機器:M&Aディール及び事業提携情報
    Summary Titan Pharmaceuticals Inc (Titan) is a pharmaceutical company that develops therapeutics for the treatment of serious medical disorders. The company develops drugs using ProNeura, a proprietary drug delivery platform, for the treatment of chronic diseases. It product portfolio provides probu …
  • Beltrami Electric Cooperative, Inc.:発電所・企業SWOT分析
    Beltrami Electric Cooperative, Inc. - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information …
  • GlaxoSmithKline Pharmaceuticals Ltd (GLAXO):企業の財務・戦略的SWOT分析
    GlaxoSmithKline Pharmaceuticals Ltd (GLAXO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key streng …
  • Sanwa Holdings Corporation:企業の戦略・SWOT・財務情報
    Sanwa Holdings Corporation - Strategy, SWOT and Corporate Finance Report Summary Sanwa Holdings Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Burgan Bank Sak:企業の戦略・SWOT・財務分析
    Burgan Bank Sak - Strategy, SWOT and Corporate Finance Report Summary Burgan Bank Sak - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Oncomatryx Biopharma SL:製薬・医療:M&Aディール及び事業提携情報
    Summary Oncomatryx Biopharma SL (Oncomatryx) is a developer of precision drugs. The company offers precision drugs that targets proteins located in the tumor environment. It develops therapeutic antibody-drug conjugates, antibodies, and human-derived proteins, which targets tumor associated stroma. …
  • QBE Insurance Group Limited:戦略・SWOT・企業財務分析
    QBE Insurance Group Limited - Strategy, SWOT and Corporate Finance Report Summary QBE Insurance Group Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Rabobank Group:企業のM&A・事業提携・投資動向
    Rabobank Group - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Rabobank Group Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestmen …
  • TechnologyOne Ltd (TNE):企業の財務・戦略的SWOT分析
    TechnologyOne Ltd (TNE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Braile Biomedica Ltda:製品パイプライン分析
    Summary Braile Biomedica Ltda (Braile Biomedica) is a medical device company that develops biological, cardiovascular, electromechanical, endovascular, and oncology products. The company’s cardiovascular products comprise wirewound arterial cannula, anterograde cardioplegia cannula, wirewound venous …
  • Paychex, Inc. (PAYX):企業の財務・戦略的SWOT分析
    Paychex, Inc. (PAYX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Alexander & Baldwin Inc (ALEX):企業の財務・戦略的SWOT分析
    Alexander & Baldwin Inc (ALEX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Alliqua BioMedical Inc (ALQA):製薬・医療:M&Aディール及び事業提携情報
    Summary Alliqua BioMedical Inc (Alliqua BioMedical), formerly HepaLife Technologies Inc, is a regenerative technology company that builds a suite of regenerative solutions for wound and tissue repair. The company’s products comprise ultrasound healing therapy, human biologics, antimicrobial protecti …
  • Tetra Technologies, Inc.
    Tetra Technologies, Inc. - Strategy, SWOT and Corporate Finance Report Summary Tetra Technologies, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Siemens AG (SIE):医療機器:M&Aディール及び事業提携情報
    Summary Siemens AG (Siemens) is a technology company that offers products and solutions for electrification, automation and digitization. The company offers products, services and solutions for power generation, transmission and distribution; oil and gas production and transportation; medical imagin …
  • United Technologies Corp (UTX):企業の財務・戦略的SWOT分析
    United Technologies Corp (UTX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • OAO Lukoil:企業のM&A・事業提携・投資動向
    OAO Lukoil - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's OAO Lukoil Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capi …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆